Sienna Biopharmaceuticals, Inc.
Other OTCTotal Valuation
Sienna Biopharmaceuticals, Inc. carries a market capitalization of 3,091.00, placing it among publicly traded companies globally. Its enterprise value stands at -6.01M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3,091.00 |
| Enterprise Value | -6.01M |
Share Statistics
Sienna Biopharmaceuticals, Inc. currently has 30.77M shares outstanding.
| Shares Outstanding | 30.77M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.03 |
| P/TBV Ratio | -13.34 |
| P/FCF Ratio | -0.10 |
| P/OCF Ratio | -0.10 |
Financial Position
Sienna Biopharmaceuticals, Inc. maintains a current ratio of 15.27, meaning it holds 15.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 15.27 |
| Quick Ratio | 8.77 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -57.04 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -4.62M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Sienna Biopharmaceuticals, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -52.02M, while operating income came in at -52.18M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -52.18M |
| Pretax Income | -52.57M |
| Net Income | -47.95M |
| EBITDA | -52.02M |
| EBIT | -52.18M |
| Earnings Per Share (EPS) | -1.80 |
Balance Sheet
Total book value stands at -188.02M, with working capital of 18.44M providing operational flexibility.
| Cash & Cash Equivalents | 11.33M |
| Total Debt | N/A |
| Net Debt | -11.33M |
| Equity (Book Value) | -188.02M |
| Book Value Per Share | -7.06 |
| Working Capital | 18.44M |
Cash Flow
Sienna Biopharmaceuticals, Inc. produced -54.63M in operating cash flow over the past twelve months. After subtracting -10,000.00 in capital expenditures, free cash flow totaled -54.64M - equivalent to -2.05 per share.
| Operating Cash Flow | -54.63M |
| Capital Expenditures | -10,000.00 |
| Free Cash Flow | -54.64M |
| FCF Per Share | -2.05 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -40.77 |
| FCF Yield | -1,025.80 |
Scores
Sienna Biopharmaceuticals, Inc. posts an Altman Z-Score of -20.52, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -20.52 |